Online inquiry

IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6520MR)

This product GTTS-WQ6520MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ALCAM gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001243280.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 214
UniProt ID Q13740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6520MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10283MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LGT209
GTTS-WQ8538MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Hu5A8
GTTS-WQ10809MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA M777-16-3
GTTS-WQ7512MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GC-1102
GTTS-WQ946MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ3171MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ10988MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ3801MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY-86-6150
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW